JHVEphoto / Shutterstock.com
13 April 2023AmericasStaff writer
Fed Circuit refuses to revive Parkinson’s disease patent
Precedential decision upholds lower court’s earlier finding | Patent at heart of the dispute covers treatment patch for Parkinson’s.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Americas
3 July 2013 Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Americas
25 June 2019 The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro, a patch to treat Parkinson’s disease.
Editor's picks
Editor's picks
Americas
3 July 2013 Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Americas
25 June 2019 The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro, a patch to treat Parkinson’s disease.
Americas
3 July 2013 Belgian pharmaceutical company UCB SA has sued drug-maker Teva Pharmaceutical Industries to stop it manufacturing a generic version of epilepsy drug Vimpat.
Americas
25 June 2019 The US Court of Appeals for the Federal Circuit yesterday, June 24, upheld a lower court’s finding that UCB’s patent is infringed by a planned generic version of Neupro, a patch to treat Parkinson’s disease.